financetom
Market
financetom
/
Market
/
PB Fintech to invest a sum of ₹350 crore in wholly-owned subsidiary Policybazaar
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PB Fintech to invest a sum of ₹350 crore in wholly-owned subsidiary Policybazaar
Nov 27, 2023 1:11 AM

PB Fintech Ltd., a financial services platform has invested an additional sum of ₹350 crore in its wholly-owned subsidiary Policybazaar Insurance Brokers Pvt. Ltd.

Share Market Live

NSE

The investment in the Gurugram-based subsidiary was done at an arm's length basis, the company said in an exchange filing.

PB Fintech said that the current investment will allow Policybazaar to strengthen its financial health, meet general operating expenses and enhance brand awareness, office presence and strategic initiatives.

The funds will be infused in one or more tranches across financial year 2024 and 2025. The investment has been made at a price of ₹603 apiece, post which, 58 lakh shares of Policybazaar have been allotted to the parent company.

In December 2021, PB Fintech had announced that it will invest up to ₹700 crore in Policybazaar in one or more tranches during financial year 2022 and 2023. It also announced an investment of ₹230 crore in Paisabazaar Marketing and Consulting Pvt. Ltd., a digital marketplace for consumer credit.

In a clarification issued to the exchanges on September 11, PB Fintech mentioned that it has no intentions of becoming a direct insurer or applying for such a license, emphasising its commitment to maintaining a harmonious relationship with existing insurance partners.

CNBC-TV18 had reported that PB Fintech is looking at bringing some significant diversification into its business lines.

Having listed two years earlier in November 2021, PB Fintech's shares are trading close to their 52-week high of ₹846.5, but continue to remain below its issue price of ₹980.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US STOCKS-Wall Street ends higher with Nasdaq up more than 1%, led by Apple
US STOCKS-Wall Street ends higher with Nasdaq up more than 1%, led by Apple
Aug 6, 2025
(Updates close with volume, share moves) * Apple ( AAPL ) to announce $100-billion pledge, says White House official * S&P 500 earnings reports continue to be better than expected * Indexes: Dow up 0.2%, S&P 500 up 0.7%, Nasdaq up 1.2% By Caroline Valetkevitch NEW YORK Aug 6 (Reuters) - U.S. stocks ended higher on Wednesday, led by a...
Centerra Gold Q2 Adjusted Profit Rises 14% on Higher Gold Prices; Advances Its Goldfield Project to Construction
Centerra Gold Q2 Adjusted Profit Rises 14% on Higher Gold Prices; Advances Its Goldfield Project to Construction
Aug 6, 2025
05:15 PM EDT, 08/06/2025 (MT Newswires) -- Centerra Gold ( CGAU ) shares were last seen up 1.7% in after-hours New York trading after the companyh on Wednesday said its second-quarter adjusted profit rose 14% as it said it will move forward on construction of its Goldfield project in Nevada. The company said its adjusted profit, excluding most one-time items,...
Research Alert: Cor Beats Jun-q Eps Expectations, Raises Guidance On U.s. Pharma Profitability
Research Alert: Cor Beats Jun-q Eps Expectations, Raises Guidance On U.s. Pharma Profitability
Aug 6, 2025
05:25 PM EDT, 08/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: COR delivered a strong Jun-Q, with EPS of $4.00 vs. $3.34 (+19.8% Y/Y) beating consensus by $0.16. Revenue of $80.7B rose 8.7% Y/Y, 0.7% above consensus. U.S. Healthcare segment sales...
Research Alert: Mck Kicks Off Fy 26 With Eps/sales Beat; Guidance Raised On U.s. Pharma
Research Alert: Mck Kicks Off Fy 26 With Eps/sales Beat; Guidance Raised On U.s. Pharma
Aug 6, 2025
06:50 PM EDT, 08/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: MCK released Q1 FY 26 results above consensus, with adjusted EPS of $8.26 (+4.8% Y/Y) topping the $8.15 expectation. Sales of $97.8B (+23.4% Y/Y) exceeded the $96.3B consensus. Continued strength...
Copyright 2023-2025 - www.financetom.com All Rights Reserved